What was the primary driver of Stryker's sales growth in the first nine months of 2003?

Stryker's net sales growth of 20% was driven by a combination of factors including increased unit volume and favorable product mix (12%), changes in foreign currency exchange rates (4%), higher selling prices (2%), and contributions from acquired businesses and product lines (2%).

How did the company manage its expenses in relation to revenue growth?

Stryker effectively managed its expenses. Cost of sales as a percentage of net sales slightly decreased, and while R&D and SG&A expenses increased in absolute terms, they generally grew in line with or slightly below sales growth, indicating good operational leverage. The absence of significant restructuring charges from the prior year also contributed to improved net earnings.

What is the company's outlook regarding liquidity and capital resources?

Stryker maintains a strong liquidity position with $45.3 million in cash and cash equivalents and significant available borrowing capacity of $907.6 million under its credit facilities. The company generated substantial operating cash flow and believes its cash on hand, anticipated cash flows, and credit facilities will be sufficient to fund future operations, investments, and debt repayments.

Are there any significant one-time items impacting the current period's results compared to the prior year?

The prior year's comparable period (nine months ended September 30, 2002) included significant restructuring and acquisition-related charges totaling $17.2 million. The absence of these charges in the current year's reporting period contributes to the substantial year-over-year percentage increase in net earnings.

SYK 10-Q Quarterly Report Q3 FY2003 — Revenue, Net Income, EPS

Summary

Stryker Corporation (SYK) reported strong financial performance for the nine months ended September 30, 2003, demonstrating significant year-over-year growth across key metrics. Net sales increased by 20% to $2.624 billion, driven by robust performance in both the Orthopaedic Implants and MedSurg Equipment segments. This top-line growth translated into substantial earnings improvement, with net earnings rising 33% to $319.4 million, or $1.57 per diluted share. The company also showcased healthy operational cash flow, generating $445.8 million, which was used to fund capital expenditures, acquisitions, and debt repayments. The company's operational efficiency is highlighted by improvements in gross profit margin and a controlled increase in operating expenses relative to sales growth. While R&D expenses saw an increase to support future product development, this was effectively managed within the overall sales increase. The balance sheet remains solid, with increased working capital and ample liquidity available through credit facilities, positioning Stryker favorably for continued growth and investment in innovation.

Key Highlights

1Stryker reported a 20% increase in net sales for the first nine months of 2003, reaching $2.624 billion, compared to $2.182 billion in the prior year.
2Net earnings for the nine-month period grew by 33% to $319.4 million, with diluted EPS increasing to $1.57 from $1.18.
3The Orthopaedic Implants segment showed strong growth, with sales up 23% year-over-year for the nine months.
4MedSurg Equipment segment sales increased by 17% for the first nine months of 2003.
5Operating cash flow was robust, generating $445.8 million for the nine-month period, up from $332.1 million in the prior year.
6The company maintained a strong liquidity position with $45.3 million in cash and cash equivalents and $907.6 million in available borrowing capacity.
7Restructuring and acquisition-related charges from 2002 were fully lapped, contributing to a significant year-over-year percentage increase in net earnings for the current period.

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2003

Summary

Key Highlights

Frequently Asked Questions